Overview Dividends

(KYMR) Kymera Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5015751044

IRAK4, STAT6, TYK2, Protein Degradation

Biotechnology
Market Cap in USD: 6,370m
IPO / Inception: 2020-08-21
Return 12m vs S&P 500: 77.8%

EPS (Earnings per Share)

EPS (Earnings per Share) of KYMR over the last years for every Quarter: "2020-12": -0.29, "2021-03": -0.29, "2021-06": -0.55, "2021-09": -0.56, "2021-12": -0.66, "2022-03": -0.71, "2022-06": -0.78, "2022-09": -0.79, "2022-12": -0.6, "2023-03": -0.7, "2023-06": -0.67, "2023-09": -0.9, "2023-12": -0.25, "2024-03": -0.62, "2024-06": -0.58, "2024-09": -0.82, "2024-12": -0.89, "2025-03": -0.82, "2025-06": -0.95, "2025-09": -0.94,
EPS CAGR: -32.28%
EPS Trend: -32.1%
Last SUE: -0.55
Qual. Beats: 0

Revenue

Revenue of KYMR over the last years for every Quarter: 2020-12: 12.785, 2021-03: 18.702, 2021-06: 18.519, 2021-09: 20.336, 2021-12: 15.275, 2022-03: 9.622, 2022-06: 11.514, 2022-09: 9.551, 2022-12: 16.139, 2023-03: 9.466, 2023-06: 16.513, 2023-09: 4.728, 2023-12: 47.885, 2024-03: 10.287, 2024-06: 25.65, 2024-09: 3.741, 2024-12: 7.394, 2025-03: 22.1, 2025-06: 11.476, 2025-09: 2.764,
Rev. CAGR: -36.61%
Rev. Trend: -31.5%
Last SUE: -1.95
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 74.2%
Value at Risk 5%th 107%
Relative Tail Risk -12.10%
Reward TTM
Sharpe Ratio 1.23
Alpha 78.63
CAGR/Max DD 0.66
Character TTM
Hurst Exponent 0.535
Beta 1.552
Beta Downside 1.456
Drawdowns 3y
Max DD 71.69%
Mean DD 23.23%
Median DD 19.07%

Description: KYMR Kymera Therapeutics November 08, 2025

Kymera Therapeutics (NASDAQ:KYMR) is a clinical-stage biotech that designs small-molecule degraders-often called PROTACs-to harness the body’s ubiquitin-proteasome system and eliminate disease-causing proteins.

The company’s lead pipeline centers on an IRAK4 inhibitor currently in a Phase II trial for hidradenitis suppurativa and atopic dermatitis, with a second STAT6-targeted candidate for type 2 inflammatory disorders and a TYK2 program aimed at broader autoimmune indications.

Kymera has a strategic alliance with Sanofi that provides an upfront payment of roughly $50 million and up to $300 million in milestone potential for non-oncology IRAK4 programs, giving the firm a non-dilutive cash infusion and validation of its degrader platform.

As of the latest 10-Q, Kymera reported cash and equivalents of about $200 million, supporting roughly 18 months of runway at its current burn rate of $70 million per year; the biotech sector’s R&D spend is growing at a 9 % CAGR, while the global targeted protein degradation market is projected to expand at ~14 % CAGR through 2030, underscoring a favorable macro backdrop for Kymera’s technology.

For a deeper quantitative view, the ValueRay platform offers a granular breakdown of KYMR’s valuation metrics and comparable peer analysis.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-295.1m TTM) > 0 and > 6% of Revenue (6% = 2.62m TTM)
FCFTA -0.21 (>2.0%) and ΔFCFTA -6.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 1044 % (prev 573.5%; Δ 470.8pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.21 (>3.0%) and CFO -227.9m > Net Income -295.1m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 7.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (87.3m) change vs 12m ago 14.68% (target <= -2.0% for YES)
Gross Margin -83.38% (prev 92.85%; Δ -176.2pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 4.09% (prev 8.46%; Δ -4.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -875.0 (EBITDA TTM -285.9m / Interest Expense TTM 337.0k) >= 6 (WARN >= 3)

Altman Z'' -8.62

(A) 0.41 = (Total Current Assets 528.3m - Total Current Liabilities 71.6m) / Total Assets 1.10b
(B) -0.89 = Retained Earnings (Balance) -979.0m / Total Assets 1.10b
(C) -0.28 = EBIT TTM -294.9m / Avg Total Assets 1.07b
(D) -6.27 = Book Value of Equity -977.5m / Total Liabilities 155.8m
Total Rating: -8.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.08

1. Piotroski 0.0pt
2. FCF Yield -3.87%
3. FCF Margin data missing
4. Debt/Equity 0.09
5. Debt/Ebitda 0.10
6. ROIC - WACC (= -37.90)%
7. RoE -33.35%
8. Rev. Trend -31.53%
9. EPS Trend -32.11%

What is the price of KYMR shares?

As of December 22, 2025, the stock is trading at USD 83.99 with a total of 1,452,964 shares traded.
Over the past week, the price has changed by -1.97%, over one month by +27.18%, over three months by +64.65% and over the past year by +105.91%.

Is KYMR a buy, sell or hold?

Kymera Therapeutics has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy KYMR.
  • Strong Buy: 14
  • Buy: 3
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the KYMR price?

Issuer Target Up/Down from current
Wallstreet Target Price 115.6 37.6%
Analysts Target Price 115.6 37.6%
ValueRay Target Price 88.1 4.8%

KYMR Fundamental Data Overview December 20, 2025

Market Cap USD = 6.37b (6.37b USD * 1.0 USD.USD)
P/S = 145.6573
P/B = 6.7321
Beta = 2.287
Revenue TTM = 43.7m USD
EBIT TTM = -294.9m USD
EBITDA TTM = -285.9m USD
Long Term Debt = 84.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 84.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -29.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.95b USD (6.37b + Debt 84.0m - CCE 505.7m)
Interest Coverage Ratio = -875.0 (Ebit TTM -294.9m / Interest Expense TTM 337.0k)
FCF Yield = -3.87% (FCF TTM -230.2m / Enterprise Value 5.95b)
FCF Margin = -526.4% (FCF TTM -230.2m / Revenue TTM 43.7m)
Net Margin = -674.8% (Net Income TTM -295.1m / Revenue TTM 43.7m)
Gross Margin = -83.38% ((Revenue TTM 43.7m - Cost of Revenue TTM 80.2m) / Revenue TTM)
Gross Margin QoQ = -2581 % (prev 81.84%)
Tobins Q-Ratio = 5.40 (Enterprise Value 5.95b / Total Assets 1.10b)
Interest Expense / Debt = 0.12% (Interest Expense 98.0k / Debt 84.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -233.0m (EBIT -294.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.38 (Total Current Assets 528.3m / Total Current Liabilities 71.6m)
Debt / Equity = 0.09 (Debt 84.0m / totalStockholderEquity, last quarter 946.3m)
Debt / EBITDA = 0.10 (negative EBITDA) (Net Debt -29.0m / EBITDA -285.9m)
Debt / FCF = 0.13 (negative FCF - burning cash) (Net Debt -29.0m / FCF TTM -230.2m)
Total Stockholder Equity = 884.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.78% (Net Income -295.1m / Total Assets 1.10b)
RoE = -33.35% (Net Income TTM -295.1m / Total Stockholder Equity 884.9m)
RoCE = -30.43% (EBIT -294.9m / Capital Employed (Equity 884.9m + L.T.Debt 84.0m))
RoIC = -26.33% (negative operating profit) (NOPAT -233.0m / Invested Capital 884.9m)
WACC = 11.58% (E(6.37b)/V(6.45b) * Re(11.73%) + D(84.0m)/V(6.45b) * Rd(0.12%) * (1-Tc(0.21)))
Discount Rate = 11.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.14%
Fair Price DCF = unknown (Cash Flow -230.2m)
EPS Correlation: -32.11 | EPS CAGR: -32.28% | SUE: -0.55 | # QB: 0
Revenue Correlation: -31.53 | Revenue CAGR: -36.61% | SUE: -1.95 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.97 | Chg30d=+0.014 | Revisions Net=+6 | Analysts=9
EPS next Year (2026-12-31): EPS=-3.73 | Chg30d=+0.082 | Revisions Net=+2 | Growth EPS=-7.8% | Growth Revenue=-11.2%

Additional Sources for KYMR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle